Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly’s dominance

by | May 4, 2026 | Uncategorized

Early signs from the launch of Novo Nordisk’s Wegovy pill and Eli Lilly & Co.’s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments